Algeria
Tuberculosis profile
Population  2012 38 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5.6 (1.9–11) 15 (5.1–29)
Mortality (HIV+TB only) 0.028 (0.018–0.034) 0.07 (0.05–0.09)
Prevalence  (includes HIV+TB) 59 (25–110) 152 (66–274)
Incidence  (includes HIV+TB) 34 (25–45) 89 (65–117)
Incidence (HIV+TB only) 0.086 (0.063–0.11) 0.22 (0.16–0.29)
Case detection, all forms (%) 64 (49–87)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 7 510 (35) Relapse 374 (65)
Smear-negative 1 581 (7) Treatment after failure 35 (6)
Smear-unknown / not done 121 (<1) Treatment after default 105 (18)
Extrapulmonary 12 294 (57) Other 62 (11)
Other 0 (0)      
Total new 21 506   Total retreatment 576  
           
Other (history unknown) 0        
Total new and relapse 21 880   Total cases notified 22 082  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.6    
Age < 15 89    
Laboratories 2012
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 3.8
Drug susceptibility testing (per 5 million population) 0.3
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 92   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 94  
Retreatment 80  
TB/HIV 2012 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 2 377  
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.6–2.7) 9.1 (1.1–29)
MDR-TB cases among notified pulmonary
TB cases
130 (56–250) 52 (7–170)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases      
Patients started on MDR-TB treatment      
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-21 Data: www.who.int/tb/data